Cll Pharma

Calculating rank

USPTO Granted Patents = 5

% Expired Patents = 80.0

EPO Patents = 3

Forward Citations = 87

Loading Chart...

6 inventors (with patents filed for the assignee):

Claude Laruelle (5 out of 24 patents)

Jamal Temsamani (2 out of 9 patents)

Dominique Toselli (1 out of 2 patents)

4. René Gimet (1 out of 2 patents)

5. Noël Zakarian (1 out of 2 patents)

6. Thierry Breul (1 out of 7 patents)

5 patents: Sort by Forward Citations

1. 9427455 - Use of the pat nanopeptide in the treatment of autoimmune diseases (2016-08-30),

2. 9192654 - Use of the PAT nanopeptide in treating and preventing neurodegenerative diseases (2015-11-24),

3. 9029390 - Oral composition containing an antiplatelet agent of the thienopyridine family in the form of free base (2015-05-12),

4. 6669957 - Galenic formulations fast disintegrating in the mouth and method for preparing same (2003-12-30),

5. 5827536 - Pharmaceutical dosage formulations of fenofibrate and their applications (1998-10-27),

Company Overview

CLL Pharma is a leading pharmaceutical company focused on developing innovative solutions for various health challenges. With a strong commitment to research and development, we strive to bring high-quality and affordable medications to patients around the world. Our dedicated team of experts works tirelessly to improve healthcare outcomes and enhance the quality of life for individuals in need.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

5 Patents

#5 in Nice

#2,868 in France

Nice, France

Cll Pharma

Forward Citations = 87

6 inventors:

Claude Laruelle (5 out of 24 patents)

Jamal Temsamani (2 out of 9 patents)

Dominique Toselli (1 out of 2 patents)

4. René Gimet (1 out of 2 patents)

5. Noël Zakarian (1 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cll Pharma. Retrieved from https://idiyas.com/company/cll-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

3 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]